| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Net revenue | 784,513 | 724,508 | 695,420 | 702,468 |
| Cost of goods sold | 510,539 | 438,255 | 439,529 | 432,910 |
| Gross profit | 273,974 | 286,253 | 255,891 | 269,558 |
| Selling, general and administrative | 137,815 | 124,266 | 118,288 | 118,692 |
| Intellectual property legal development expenses | - | - | - | 1,967 |
| Research and development | 63,352 | 47,964 | 40,040 | 61,097 |
| Intellectual property legal development expenses | 2,437 | 2,017 | 1,767 | - |
| Change in fair value of contingent consideration | - | - | - | 1,030 |
| Restructuring and other charges | 143 | 1,024 | 571 | 172 |
| (credit) charges related to legal matters, net | 0 | 390 | - | 149 |
| Other operating income | 117 | 0 | 5,122 | - |
| Operating income (loss) | 70,344 | 111,372 | 100,347 | 88,809 |
| Interest expense, net | -62,814 | -65,101 | -56,939 | -65,511 |
| Foreign exchange (loss) gain, net | -3,431 | 8,256 | 4,247 | 2,274 |
| Decrease (increase) in tax receivable agreement liability | 20,808 | -4,420 | -10,687 | -11,327 |
| Loss on refinancing | -31,365 | - | - | - |
| Other income, net | 1,235 | 1,604 | 518 | 1,178 |
| Total other expense, net | -75,567 | -59,661 | -62,861 | -73,386 |
| Income (loss) before income taxes | -5,223 | 51,711 | 37,486 | 15,423 |
| (benefit from) provision for income taxes | -23,355 | 16,101 | 12,868 | 3,666 |
| Net income (loss) | 18,132 | 35,610 | 24,618 | 11,757 |
| Basic (in dollars per share) | 0.01 | 0.07 | 0.04 | 0 |
| Basic (in shares) | 314,168,000 | 313,739,000 | 311,054,000 | 309,647,000 |
| Diluted (in dollars per share) | 0.01 | 0.07 | 0.04 | 0 |
| Diluted (in shares) | 324,754,000 | 322,363,000 | 323,961,000 | 309,647,000 |
Amneal Pharmaceuticals, Inc. (AMRX)
Amneal Pharmaceuticals, Inc. (AMRX)